Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection - Tenofovir Alafenamide (TAF) Children and Adolescents

Next Previous
Trial Profile

A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection - Tenofovir Alafenamide (TAF) Children and Adolescents

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir alafenamide (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 29 Jul 2025 Status changed from recruiting to active, no longer recruiting.
  • 29 Jul 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.
  • 28 Mar 2024 According to a Gilead Sciences media release, the U.S. FDA has approved the supplemental NDA for Vemlidy 25mg tablets (once daily) treatment for chronic HBV infection in patients 6 yrs and older & weighing at least 25 kg with compensated liver disease. Approval is supported by Wk 96 data from this trial comparing treatment with Vemlidy 25mg to placebo among 18 treatment-naive and treatment-experienced patients aged 6 to less than 12 yrs weighing at least 25kg (Cohort 2, Group 1).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top